RWF_CDX1127-02

A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects. The study will enroll patients with the following cancer types: Non-Small Cell Lung Cancer, Melanoma, Colorectal, Ovarian or Head and Neck Squamous Cell Carcinoma.

Key Inclusion Criteria:

* Histologically-diagnosed advanced (unresectable and/or metastatic) Non-small Cell Lung Cancer, Melanoma, Colorectal, Head and Neck SCC (squamous cell carcinoma), or Ovarian Cancer.

* No more than 5 prior anticancer regimens for advanced (recurrent, locally advanced or metastatic) disease.
Phase I/II
NCT02335918
Oncology
Multiple Tumor Types
Rachel Sanborn, M.D.
Celldex
Tara Foote
  • Oncology and Hematology Care Eastside